A Randomized ,Open Label Study Comparing the Efficacy of Zoladex Combined With Arimidex for 3-2 Years After Selective Estrogen Receptor Modulators (SERMs) as an Adjuvant Therapy for 2-3 Years Versus Continuing Tamoxifen up to 5 Years for Premenopausal Early Breast Cancer Patients With Hormone Receptor Positive, Lymph Node Positive or Tumor >=4cm.

Trial Profile

A Randomized ,Open Label Study Comparing the Efficacy of Zoladex Combined With Arimidex for 3-2 Years After Selective Estrogen Receptor Modulators (SERMs) as an Adjuvant Therapy for 2-3 Years Versus Continuing Tamoxifen up to 5 Years for Premenopausal Early Breast Cancer Patients With Hormone Receptor Positive, Lymph Node Positive or Tumor >=4cm.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Goserelin (Primary) ; Anastrozole; Tamoxifen
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top